Moderna Inc
MRNA27.980USD
+1.290+4.83%
Market hours （ET）Quotes delayed by 15 min
10.88BMarket Cap
LossP/E TTM
More Details of Moderna Inc Company
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.
Company Info
Ticker SymbolMRNA
Company nameModerna Inc
IPO dateDec 07, 2018
CEOMr. Stephane Bancel
Number of employees5800
Security typeOrdinary Share
Fiscal year-endDec 07
Address325 Binney Street
CityCAMBRIDGE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02142
Phone16177146500
Websitehttps://www.modernatx.com/
Ticker SymbolMRNA
IPO dateDec 07, 2018
CEOMr. Stephane Bancel
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.61M
+0.09%
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
+6.84%
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
26.89K
+2.24%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
16.94K
+4.63%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
3.08K
+46.51%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
703.00
--
Dr. Noubar B. Afeyan, Ph.D.
Dr. Noubar B. Afeyan, Ph.D.
Non-Executive Independent Chairman of the Board, Co-Founder
Non-Executive Independent Chairman of the Board, Co-Founder
--
--
Dr. Rose Loughlin
Dr. Rose Loughlin
Executive Vice President - Research
Executive Vice President - Research
--
--
Mr. Jerh Collins
Mr. Jerh Collins
Chief Technical Operations and Quality Officer
Chief Technical Operations and Quality Officer
--
--
Mr. Stephane Bancel
Mr. Stephane Bancel
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.61M
+0.09%
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
+6.84%
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
26.89K
+2.24%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
16.94K
+4.63%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
3.08K
+46.51%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
703.00
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
COVID
84.00M
97.67%
RSV
2.00M
2.33%
By RegionUSD
Name
Revenue
Proportion
Rest of the World
55.00M
63.95%
United States
31.00M
36.05%
Europe
0.00
0.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
COVID
84.00M
97.67%
RSV
2.00M
2.33%
Shareholding Stats
Updated: 15 hours ago
Updated: 15 hours ago
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.70%
Baillie Gifford & Co.
5.68%
BlackRock Institutional Trust Company, N.A.
5.05%
Fidelity Management & Research Company LLC
5.00%
State Street Global Advisors (US)
4.44%
Other
69.14%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.70%
Baillie Gifford & Co.
5.68%
BlackRock Institutional Trust Company, N.A.
5.05%
Fidelity Management & Research Company LLC
5.00%
State Street Global Advisors (US)
4.44%
Other
69.14%
Shareholder Types
Shareholders
Proportion
Investment Advisor
39.86%
Investment Advisor/Hedge Fund
15.08%
Hedge Fund
7.39%
Corporation
4.65%
Research Firm
4.56%
Individual Investor
2.55%
Bank and Trust
2.15%
Pension Fund
1.20%
Venture Capital
1.20%
Other
21.35%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
2015
310.55M
79.82%
-10.63M
2025Q1
2127
325.75M
84.24%
-21.87M
2024Q4
2176
321.41M
83.21%
-6.67M
2024Q3
2154
311.92M
81.18%
-17.40M
2024Q2
2186
316.03M
82.47%
-13.47M
2024Q1
2203
318.24M
83.12%
-1.14M
2023Q4
2309
311.40M
81.63%
+3.41M
2023Q3
2445
301.25M
79.05%
-6.86M
2023Q2
2461
301.15M
78.90%
-7.01M
2023Q1
2466
303.08M
78.58%
-1.88M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
40.25M
10.41%
+71.93K
+0.18%
Mar 31, 2025
Baillie Gifford & Co.
24.95M
6.45%
-13.94M
-35.85%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
17.87M
4.62%
-166.51K
-0.92%
Mar 31, 2025
Fidelity Management & Research Company LLC
20.83M
5.39%
+2.44M
+13.30%
Mar 31, 2025
State Street Global Advisors (US)
17.78M
4.6%
+201.32K
+1.15%
Mar 31, 2025
Two Sigma Investments, LP
8.26M
2.14%
+7.49M
+976.22%
Mar 31, 2025
Boston Biotech Ventures, L.L.C.
9.21M
2.38%
+160.31K
+1.77%
Mar 05, 2025
Geode Capital Management, L.L.C.
7.46M
1.93%
+215.24K
+2.97%
Mar 31, 2025
Theleme Partners LLP
7.24M
1.87%
-64.47K
-0.88%
Mar 31, 2025
D. E. Shaw & Co., L.P.
5.64M
1.46%
+3.87M
+218.66%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
4.09%
Global X Genomics & Biotechnology ETF
4.08%
First Trust NYSE Arca Biotechnology Index Fund
3.31%
SPDR S&P Biotech ETF
2.42%
VanEck Biotech ETF
2.35%
Virtus LifeSci Biotech Products ETF
1.94%
Langar Global HealthTech ETF
1.9%
WisdomTree BioRevolution Fund
1.66%
Invesco S&P 500 Equal Weight Health Care ETF
1.65%
ROBO Global Healthcare Technology & Innovation ETF
1.43%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion4.09%
Global X Genomics & Biotechnology ETF
Proportion4.08%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.31%
SPDR S&P Biotech ETF
Proportion2.42%
VanEck Biotech ETF
Proportion2.35%
Virtus LifeSci Biotech Products ETF
Proportion1.94%
Langar Global HealthTech ETF
Proportion1.9%
WisdomTree BioRevolution Fund
Proportion1.66%
Invesco S&P 500 Equal Weight Health Care ETF
Proportion1.65%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.43%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
